Abstract 5862: Racial disparities in pancreatic cancer: A quantitative proteo-genomic analysis

Digonto Chatterjee,Jack Hester,Meera Srivastava,Alakesh Bera
DOI: https://doi.org/10.1158/1538-7445.am2022-5862
IF: 11.2
2022-06-17
Cancer Research
Abstract:Pancreatic cancer remains a major health concern, being among the most deadly forms of cancer. It is the seventh most common cancer, yet it is the third leading cause of cancer deaths in the United States. It is estimated that in 2021, 48,220 patients will die from pancreatic cancer. Risk factors for pancreatic cancer include smoking, diabetes, obesity, chronic pancreatitis, and family history. Over 80% of the patients present with metastatic disease. Despite advances in chemotherapy, the average survival remains less than 5 years even after surgery. Genetic research on pancreatic cancer has generally only focused on familial pancreatic cancer, which is only 10% of all pancreatic cancer patients. This study focuses on finding genes that impact the survival of pancreatic cancer patients based on race, with the goal of finding genes that are race specific and can be used as biomarkers and potential targets to develop personalized treatment options. All datasets for pancreatic cancer in cBioPortal were used for this study. The data were then stratified based on race information for the patients. Three (3) racial categories, 1) White 2) African American and Black, and 3) Asian were chosen. Our analysis finds that White, African Americans and Asians have distinct copy number alterations, more specifically amplifications in specific genes, with GATA6, RECQL4, and MIB1 being only altered in White patients, PKD1L1, GARS1, and NEUROD6 only altered in Black & African American patients, and the entire 4p16.3 cytoband of genes (39 in total), only altered in Asian patients. Patients with alterations in these unique genes also had poor survival. Using the Protein Atlas, MD Anderson Cell Lines Project (MCLP) dataset and genecards.org data, we identified potential drug candidates that target the proteins encoded by these genes. Our study clearly demonstrates that race specific genetic alterations exist in pancreatic cancer and provides a foundation for the development of race specific diagnostic/prognostic biomarkers and targeted therapeutic options with better survival outcomes. Citation Format: Digonto Chatterjee, Jack Hester, Meera Srivastava, Alakesh Bera. Racial disparities in pancreatic cancer: A quantitative proteo-genomic analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5862.
oncology
What problem does this paper attempt to address?